Bionano Genomics, Inc. short interest in 2023
In 2023, Bionano Genomics, Inc.'s disclosed short interest ran from 17.93% of shares outstanding on 13 Jan 2023 to 13.02% on 29 Dec 2023, a change of -4.91 percentage points. The year's high was 21.03% on 15 May 2023 and its low 13.02% on 29 Dec 2023, averaging 17.44% across 18 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 14.03 days on 31 Mar 2023. Full history: Bionano Genomics, Inc..
Cite this page
By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2023 in figures
- Start of year
- 17.93% (13 Jan 2023)
- End of year
- 13.02% (29 Dec 2023)
- Change
- -4.91 pp
- High
- 21.03% (15 May 2023)
- Low
- 13.02% (29 Dec 2023)
- Average
- 17.44%
- Highest days to cover
- 14.03 (31 Mar 2023)
- SEC filings marked
- 12
Every report in 2023
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 13 Jan 2023 | 17.93% | 7.80 | results (8-K) |
| 31 Jan 2023 | 17.60% | 8.23 | |
| 15 Feb 2023 | 16.57% | 6.97 | results (8-K) |
| 28 Feb 2023 | 19.42% | 7.62 | |
| 15 Mar 2023 | 17.89% | 8.46 | 10-K filed, results (8-K) |
| 31 Mar 2023 | 19.03% | 14.03 | |
| 14 Apr 2023 | 20.54% | 13.33 | |
| 28 Apr 2023 | 20.33% | 4.46 | results (8-K) |
| 15 May 2023 | 21.03% | 8.54 | 10-Q filed, results (8-K) |
| 31 May 2023 | 20.45% | 6.90 | |
| 15 Jun 2023 | 19.53% | 5.98 | |
| 30 Jun 2023 | 15.71% | 3.52 | |
| 14 Jul 2023 | 14.34% | 3.79 | |
| 31 Jul 2023 | 14.77% | 5.13 | |
| 15 Nov 2023 | 18.23% | 5.57 | 10-Q filed, results (8-K), results (8-K), 10-Q filed, results (8-K) |
| 30 Nov 2023 | 14.27% | 4.36 | |
| 15 Dec 2023 | 13.23% | 3.28 | |
| 29 Dec 2023 | 13.02% | 1.87 |
See also: Bionano Genomics, Inc.'s full history · most shorted US stocks of 2023 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.